Qiagen N.v. · NYSE:QGEN
Qiagen — Q1 2025 Earnings Presentation
24 slides from Qiagen's earnings presentation, May 8, 2025
Slide 1: Q1 2025 results
Q1 2025 results Solid results exceeding outlook May 7, 2025
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: Certain statements in this presentation may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amend
Slide 3: On track to achieve 2025 targets
On track to achieve 2025 targets Delivering solid financial performance Net sales and adjusted EPS exceeded outlook with higher profitability Driving growth through portfolio expansion Continuing momentum across growth pillars with important contributions to serve customers in both Life Sciences and
Slide 4: Solid results exceeding outlook
Q1 2025: Solid results exceeding outlook Growth Solid start to 2025 with broad-based growth across the portfolio $483 mn ($491 mn CER) • Net sales +7% CER to $483 mn above outlook of ~+3% Net sales • QuantiFERON +16% CER, QIAstat-Dx +37% CER; QIAcuity and QDI delivered +7% CER high-single-digit grow
Slide 5: Sales performance and key developments
Q1 2025: Sales performance and key developments Sales by product group Key developments (In $ millions at actual rates) +7% Sample • 1% CER sales decline reflecting lower demand for manual kits CER(1) technologies • Weaker instrument trends amid cautious customer spending 459 483 Sample • +16% CER g
Slide 6: Portfolio developments
Q1 2025: Portfolio developments Sample technologies: QIAstat-Dx: QIAGEN Digital Insights: Supporting global health priorities Expanding syndromic testing in the U.S. Boosting local bioinformatics capacity New malaria testing solution launched Second GI mini panel cleared in the U.S. New data center
Slide 7: Sample tech: On the offense expanding our top automation portfolio
Sample tech: On the offense expanding our top automation portfolio Low-throughput Mid-throughput High-throughput QIAmini QIAsymphony QIAsprint Connect Connect Launch 2026 Launch 2025 Launch 2026 Market Addition to QIAcube / EZ family, building Flagship system upgrade, build on Entry into high-throug
Slide 8: Significant improvement in adjusted operating profitability
Q1 2025: Significant improvement in adjusted operating profitability Adj. operating income margin Adj. EPS ahead of Q1 2025 outlook Adj. +22% to $144 million on efficiency operating gains and NeuMoDx discontinuation +4.1 ppt 29.8% income 25.7% Non- Lower than expected adjusted tax rate operating (20
Slide 9: Enhancing operating cash flow generation
Q1 2025: Enhancing operating cash flow generation Using healthy cash flows and strong balance sheet to re-invest in growth and drive shareholder returns Cash flow(1) Debt maturity overview(3) (in $ millions) 615 115 500 In $ millions Q1 2025 Q1 2024 Change Likely Operating cash flow 140 133 +5% repa
Slide 10: Outlook: Q2 and FY 2025
Outlook: Q2 and FY 2025 As of May 7, 2025 Outlook Q2 2025 FY 2025 Net sales ≥+5% CER / ~+4% CER / ≥+5% CER core portfolio(1) ~+5% CER core portfolio(1) Anticipated currency impact Positive impact of ~+1ppt Neutral FX impact Adjusted diluted EPS ≥$0.60 CER ~$2.35 CER Anticipated currency impact Neutr
Slide 11: Proposing dividend payment and $500 mn repurchase authorization
Proposing dividend payment and $500 mn repurchase authorization Profitable targeted investments Annual dividend NEW Organic initiation investments Into growth pillars and digitization to fuel profitable business expansion Seeking shareholder approval for dividend at the upcoming AGM in June 2025 Foc
Slide 12: Transition in QIAGEN Supervisory Board leadership
Transition in QIAGEN Supervisory Board leadership Stephen H. Rusckowski QIAGEN Supervisory Board members – To be elected Chairman of Supervisory Board(1) Returning to eight members as planned in 2024 • Joined Supervisory Board in 2023 • Currently Chair of Nomination & Governance Committee and member
Slide 13: Appendix
QIAGEN Appendix
Slide 14: Q2 and FY 2025: Outlook and assumptions
Q2 and FY 2025: Outlook and assumptions (As of May 7, 2025) Q2 2025 outlook FY 2025 outlook Net sales ≥+5% CER / ≥+5% CER core portfolio(1) ~+4% CER / ~+5% CER core portfolio(1) Anticipated currency impact(2) Positive impact of ~+1 ppt Neutral FX impact Adjusted diluted EPS(3) ≥$0.60 CER ~$2.35 CER
Slide 15: Consolidated Statements of Income (unaudited)
Q1 2025: Consolidated Statements of Income (unaudited) (In $ thousands, except share data) Three months ended Three months ended March 31, 2025 March 31, 2024 Net sales 483,456 458,796 Cost of sales: Cost of sales 161,294 151,734 Acquisition-related intangible amortization 13,481 16,073 Total cost o
Slide 16: 2025: Quarterly sales by product group
2025: Quarterly sales by product group (In $ millions at actual rates / Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2025 change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sample technologies 150 -3% -1% Diagnostic solutions(1) 187 9% 11% Of which QuantiFE
Slide 17: Reconciliation to adjusted results (unaudited)
Q1 2025: Reconciliation to adjusted results (unaudited) (In $ millions, except EPS) Net Gross Operating Pre-tax Income Tax Net Diluted sales profit income income tax rate income EPS* First quarter 2025 Reported results 483.5 308.7 115.3 119.5 (28.7) 24 % 90.8 0.41 Adjustments Business integration, a
Slide 18: Footnotes for reconciliation to adjusted results
Q1 2025: Footnotes for reconciliation to adjusted results (unaudited) a. Includes costs incurred in connection with streamlining operations and improving overall efficiency as well as costs related to various contemplated and completed acquisition projects and their subsequent integration. b. Adjust
Slide 19: 2025: Quarterly income statement summary
2025: Quarterly income statement summary (In $ millions, unless indicated) (Diluted EPS in $ per share) Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2025 Net sales 483.5 Net sales (CER) 491.2 Gross profit 308.7 Gross profit margin 63.8% Adjusted gross profit 325.9 Adjusted gross profit margin 67.4% Operating
Slide 20: Consolidated Balance Sheets
Consolidated Balance Sheets March 31, December 31, March 31, December 31, (In $ thousands, except par value) 2025 2024 (In $ thousands, except par value) 2025 2024 Assets (unaudited) Liabilities and Equity (unaudited) Cash and cash equivalents 638,756 663,555 Current portion of long-term debt 55,693
Slide 21: Consolidated Statements of Cash Flows (unaudited)
Consolidated Statements of Cash Flows (unaudited) Three months ended March 31, March 31, Three months ended March 31, March 31, (In $ thousands) 2025 2024 (In $ thousands) 2025 2024 Cash flows from operating activities: Cash flows from financing activities: Net income 90,758 80,673 Capital repayment
Slide 22: Currency impact
Q1 2025: Currency impact Net sales Net sales Currency exposure Change (In $ millions / Actual) (CER) (As % of CER sales) (In $ millions) Q1 2025 U.S. dollar 272.4 272.5 55% 0.1 Euro 97.7 100.6 21% 2.9 British pound 15.0 15.2 3% 0.2 Japanese yen 11.5 11.8 2% 0.3 Other currencies 87.0 91.1 19% 4.2 Tot
Slide 23: Employees as of March 31, 2025
Employees as of March 31, 2025 Europe / Middle Asia Pacific / Total Total Americas East / Africa Japan / ROW Q1 2025 Q4 2024 Change Production 340 1,245 143 1,728 1,636 6% R&D 165 627 55 847 1,001 -15% Sales 547 835 719 2,101 2,147 -2% Marketing 66 185 76 327 324 1% Administration 81 432 157 670 657
Slide 24: Your contacts
Your contacts Dr. Domenica Martorana Calendar Associate Director Global Investor Relations Annual General Meeting June 2025 Phone: +49 2103 29 11244 Q2 2025 results August 2025 E-mail: domenica.martorana@qiagen.com Q3 2025 results November 2025 Alexandra Koenig Coordinator Share information Investor